CryoPort (NASDAQ:CYRX) Shares Cross Above Two Hundred Day Moving Average – Here’s Why

31 Dec 2025, 23:26 by Amy Steele · The Cerbat Gem

CryoPort, Inc. (NASDAQ:CYRX – Get Free Report) shares passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $8.76 and traded as high as $9.69. CryoPort shares last traded at $9.55, with a volume of 291,829 shares changing hands.

Wall Street Analyst Weigh In

CYRX has been the subject of a number of research reports. UBS Group increased their price objective on CryoPort from $11.00 to $12.50 and gave the stock a “buy” rating in a report on Wednesday, November 5th. BTIG Research raised their price target on shares of CryoPort from $10.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, September 18th. Needham & Company LLC boosted their price objective on shares of CryoPort from $11.00 to $12.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of CryoPort in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $12.83.

View Our Latest Analysis on CryoPort

CryoPort Trading Down 0.4%

The company has a current ratio of 15.77, a quick ratio of 15.01 and a debt-to-equity ratio of 0.40. The business has a 50 day moving average of $9.32 and a two-hundred day moving average of $8.78. The firm has a market cap of $480.67 million, a P/E ratio of 8.21 and a beta of 1.51.

CryoPort (NASDAQ:CYRX – Get Free Report) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.05. The firm had revenue of $44.23 million for the quarter, compared to the consensus estimate of $41.22 million. CryoPort had a net margin of 35.57% and a negative return on equity of 11.07%. Analysts predict that CryoPort, Inc. will post -0.99 earnings per share for the current year.

Insider Activity at CryoPort

In other news, Director Ramkumar Mandalam sold 11,570 shares of the stock in a transaction that occurred on Wednesday, December 10th. The stock was sold at an average price of $9.99, for a total transaction of $115,584.30. Following the transaction, the director owned 80,758 shares in the company, valued at approximately $806,772.42. This trade represents a 12.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 10.00% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Jacobs Levy Equity Management Inc. grew its stake in shares of CryoPort by 283.1% in the third quarter. Jacobs Levy Equity Management Inc. now owns 524,288 shares of the company’s stock valued at $4,970,000 after acquiring an additional 387,440 shares in the last quarter. PharVision Advisers LLC boosted its holdings in CryoPort by 50.4% in the 3rd quarter. PharVision Advisers LLC now owns 16,498 shares of the company’s stock valued at $156,000 after purchasing an additional 5,531 shares during the period. Public Employees Retirement System of Ohio acquired a new position in shares of CryoPort during the 3rd quarter worth approximately $285,000. Northwestern Mutual Wealth Management Co. increased its holdings in shares of CryoPort by 45.0% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 31,556 shares of the company’s stock worth $299,000 after purchasing an additional 9,788 shares during the period. Finally, Mak Capital One LLC acquired a new stake in shares of CryoPort in the third quarter valued at approximately $7,756,000. Institutional investors own 92.90% of the company’s stock.

CryoPort Company Profile

(Get Free Report)

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.